title: Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery.
abstract: Recombinant granulocyte colony-stimulating factor (rhG-CSF) has been shown to hasten granulocyte recovery after autologous BMT. In current protocols, rhG-CSF treatment starts 1 day after BM reinfusion. Our study retrospectively examined the effects on haematological recovery of a day 6 delayed administration. Seventy-eight patients receiving autologous BMT for malignant lymphoma (21 non-Hodgkin's lymphoma and 9 Hodgkin's disease) or solid tumors (33 breast carcinoma and 5 ovarian carcinoma) were split up into three study groups. Two groups receiving a 5 micrograms/kg/day of rhG-CSF starting either 1 day (day +1 group, n = 25 patients) or 6 days (day +6 group, n = 24 patients) after BM reinfusion were compared with 29 historical control patients. Granulocyte recovery to 0.5 x 10(9)/l was 12 days in day +6 and day +1 groups versus 16 days in control group (p < 0.005) without any difference in other hematological parameters, infectious complications or length of hospitalisation between the three groups. The day +6 administration allows elimination of a median of 7 days rhG-CSF. It has been concluded that the day +6 administration gives the same clinical benefit as day +1 administration with consequent cost reductions.
authors.affiliation: Unit Institut Paoli-Calmettes, Université Aix-Marseille II, France.
authors.forename: N
authors.initials: N
authors.lastname: Vey
authors.forename: S
authors.initials: S
authors.lastname: Molnar
authors.forename: C
authors.initials: C
authors.lastname: Faucher
authors.forename: A G
authors.initials: AG
authors.lastname: Le Corroller
authors.forename: A M
authors.initials: AM
authors.lastname: Stoppa
authors.forename: P
authors.initials: P
authors.lastname: Viens
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallah
authors.forename: J
authors.initials: J
authors.lastname: Camerlo
authors.forename: G
authors.initials: G
authors.lastname: Novakovitch
authors.forename: P
authors.initials: P
authors.lastname: Mannoni
mesh_terms: D000328:Adult; D016470:Bacteremia / Q000209:etiology; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods* / Q000473:pathology; D001943:Breast Neoplasms / Q000097:blood / Q000628:therapy; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006098:Granulocytes / Q000187:drug effects* / Q000473:pathology; D006410:Hematopoiesis / Q000187:drug effects; D006689:Hodgkin Disease / Q000097:blood / Q000628:therapy; D006801:Humans; D007958:Leukocyte Count; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000628:therapy; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies; D014182:Transplantation, Autologous
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor